Mackaness James H 4

What Happened
James H. Mackaness, Chief Financial Officer of Soleno Therapeutics (SLNO), received equity awards on January 21, 2026: 28,600 restricted stock units (RSUs) and an additional 32,800 RSU-type derivative awards, for a total of 61,400 RSUs. The awards were granted at $0.00 (no cash paid). Per the filing footnotes, 28,600 RSUs vest 100% on December 15, 2027 subject to continued service; the other RSU-type awards are also subject to applicable vesting conditions.

Key Details

• Transaction date: January 21, 2026; Form 4 filed January 23, 2026 (appears timely).
• Grants: 28,600 RSUs (F1) and 32,800 RSU/derivative units (F2); total 61,400 units; $0.00 per unit.
• Shares owned after transaction: not specified in the provided filing excerpt — consult the full Form 4 for total beneficial ownership.
• Notable footnotes: F1 = 100% of the 28,600 RSUs vest on Dec 15, 2027 if the reporting person remains a service provider; F2 = additional RSUs subject to their vesting schedules; F3 references a separate option vesting schedule (1/48th monthly beginning Feb 1, 2026).
• Transaction code: A (award/grant). No sale or purchase reported.

Context
These were equity awards (RSUs), which grant a contingent right to receive shares upon vesting and do not represent an immediate cash purchase or sale. Awards are typically part of compensation and retention programs; they do not by themselves indicate buying or selling sentiment. Check the issuer's filings for total insider holdings and future vesting/calendar impacts.